JNJ-64417184
Sponsors
Janssen BioPharma, Inc., Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium
Conditions
HealthyHealthy ParticipantsRenal Impairment
Phase 1
A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants
CompletedNCT03403348
Start: 2018-05-09End: 2019-11-24Updated: 2020-01-29
A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants
CompletedNCT04090086
Start: 2019-09-16End: 2019-12-10Updated: 2025-02-03
A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets
CompletedNCT04121052
Start: 2019-10-08End: 2019-12-23Updated: 2020-01-28
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
CompletedNCT04208373
Start: 2019-12-20End: 2020-03-10Updated: 2025-02-03
A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants
CompletedNCT04258189
Start: 2020-02-11End: 2020-08-05Updated: 2025-02-03
A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
TerminatedNCT04426357
Start: 2020-07-03End: 2020-11-12Updated: 2021-01-15
A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants
CompletedNCT04453189
Start: 2020-07-20End: 2020-09-14Updated: 2025-02-03